Disclosures: Yousif Alyousifi: Nothing to Disclose, Chinmay Raut: Nothing to Disclose, Antonino Oliveri: Nothing to Disclose, Vincent Chen: AstraZeneca: site PI on industry-sponsored trial, Ipsen: site co-I on industry-sponsored trial, Kowa: site co-I on industry-sponsored trial, Elizabeth Speliotes: Nothing to Disclose 2562 DEVELOPMENT OF MUTATED B-CATENIN GENE SIGNATURE (MBGS) TO IDENTIFY CTNNB1 MUTATIONS FROM WHOLE AND SPATIAL TRANSCRIPTOMIC DATA IN PATIENTS Brandon Lehrich 1 Junyan Tao 1 Silvia Liu 1 Theo Hirsch 2 Tyler Yasaka 1 Catherine Cao 1 Evan Delgado 1 Yuqing Liu 1 Xiangnan Guan 3 Shan Lu 3 Long Pan 2 Sucha Singh 1 Minakshi Poddar 1 Aatur Singhi 4 Jessica Zucman-Rossi 5 Yulei Wang 3 Satdarshan (Paul) Monga 1 , 1 University of Pittsburgh, 2 Centre de Recherche des Cordeliers, Universit Paris Cit, Sorbonne Universit, Inserm, F-75006 Pari, 3 Translational Medicine, Genentech Inc., San Francisco, CA, USA, 4 Department of Pathology, UPMC, 5 French Institute of Health and Medical Research/Inserm Background: Hepatocellular carcinoma (HCC) is the third-leading cause of cancer-related death
Moreover, the abundance of GAMs within the perivascular niche exacerbates immunosuppression through the secretion of VEGF and PDL1 [17]
Physical activity as moderator of the association between APOE and cognitive decline in older adults: results from three longitudinal cohort studies
Interestingly, Snail and ZEB1 epigenetically repress the key gluconeogenesis enzyme fructose-1,6-bisphosphatase (FBP1), promoting the metabolic transition towards glycolysis (Molecular and C ellular Biochemistry
